1. Cytokine activation through sublethal hemorrhage is protective against early lethal endotoxic challenge.
- Author
-
Zervos EE, Norman JG, Denham DW, Carey LC, Livingston D, and Rosemurgy AS
- Subjects
- Animals, Hemorrhage mortality, Male, Mice, Mice, Inbred BALB C, Survival Analysis, Hemorrhage immunology, Interleukin-1 immunology, Lipopolysaccharides administration & dosage
- Abstract
Objectives: To determine the immunologic consequences of nonlethal hemorrhage on subsequent exposure to lipopolysaccharide (LPS) and to determine the role of interleukin 1 beta (IL-1) specifically in mediating the response to LPS with and without prior hemorrhage., Design: Prospective, randomized, controlled experimental trial., Participants: Male BALB/c mice and transgenic mice deficient in IL-1 converting enzyme., Interventions: Animals were subjected to hemorrhage (by cardiac puncture), LPS challenge by intraperitoneal injection, or hemorrhage followed 24 hours later by LPS challenge. Mortality was assessed every 4 hours for 96 hours following hemorrhage or LPS exposure. Serum IL-1 levels were determined 24 hours after exposure to hemorrhage and LPS., Setting: University of South Florida Core General Surgery Research Facility, Tampa., Main Outcome Measures: Mortality and serum IL-1 levels., Results: Hemorrhage alone resulted in complete survival, whereas LPS alone resulted in near-complete (95%) mortality. Hemorrhage, when given 24 hours before LPS challenge, afforded significant protection compared with LPS alone (67% survival vs 5% survival; P < .001). Serum IL-1 levels 24 hours after exposure to LPS were significantly lower in prehemorrhaged mice than in those receiving LPS alone. Transgenic mice incapable of producing biologically active IL-1 were further protected, demonstrating near-complete (95%) survival following hemorrhage and LPS challenge., Conclusions: Cytokine activation through nonlethal hemorrhage attenuates subsequent IL-1 response to early immunologic challenge. Such immune suppression appears to be protective early on and is supported by the near-complete immunity to LPS in animals incapable of producing biologically active IL-1.
- Published
- 1997
- Full Text
- View/download PDF